Last reviewed · How we verify

On Target Laboratories, LLC — Portfolio Competitive Intelligence Brief

On Target Laboratories, LLC pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
OTL38 for Injection OTL38 for Injection phase 3 Antibody-drug conjugate (ADC) Folate receptor alpha (FRA) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. AstraZeneca · 1 shared drug class
  3. BioAtla, Inc. · 1 shared drug class
  4. Byondis B.V. · 1 shared drug class
  5. Charite University, Berlin, Germany · 1 shared drug class
  6. Gustave Roussy, Cancer Campus, Grand Paris · 1 shared drug class
  7. Jiaxing AnDiCon Biotech Co.,Ltd · 1 shared drug class
  8. Amgen · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for On Target Laboratories, LLC:

Cite this brief

Drug Landscape (2026). On Target Laboratories, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/on-target-laboratories-llc. Accessed 2026-05-16.

Related